Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Combination of Dasatinib and Peg-Interferon Alpha 2b in First Line for Chronic Myeloid Leukemia in Chronic Phase

NCT01872442 is registered in ClinicalTrials.gov with Poitiers University Hospital as lead sponsor.

NCT NCT01872442
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01872442 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Combination of Dasatinib and Peg-Interferon Alpha 2b in First Line for Chronic Myeloid Leukemia in Chronic Phase
Lead sponsor
Poitiers University Hospital
Phase
Phase 2
Overall status
Completed
Start date
October 15, 2013
Completion date
October 31, 2018
Enrollment
Not reported
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

chronic phase of chronic myeloid leukemia